Eight Months of Serological Follow-Up of Anti-SARS-CoV-2 Antibodies in France: A Study among an Adult Population

Int J Environ Res Public Health. 2022 Nov 18;19(22):15257. doi: 10.3390/ijerph192215257.

Abstract

Background: Uncertainties remain regarding the nature and durability of the humoral immune response to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).

Aim: This study investigated immunoglobulin G response and neutralizing activity to evaluate the mean antibody concentrations and response duration induced by each vaccination regimen in a French adult population.

Methods: A study including blood sampling and questionnaires was carried out from November 2020 to July 2021 with three separate follow-up phases. Spike proteins and neutralizing antibodies were quantified using ELISA and a virus-neutralization test.

Results: Overall, 295 participants were included. Seroprevalences were 11.5% (n = 34), 10.5% (n = 31), and 68.1% (n = 201) in phases 1, 2, and 3, respectively. Importantly, 5.8% (n = 17) of participants lost their natural antibodies. Antibody response of participants with only a prior infection was 88.2 BAU/mL, significantly lower than those vaccinated, which was 1909.3 BAU/mL (p = 0.04). Moreover, the antibody response of vaccinated participants with a prior infection was higher (3593.8 BAU/mL) than those vaccinated without prior infection (3402.9 BAU/mL) (p = 0.78). Vaccinated participants with or without prior infection had a higher seroneutralization rate (91.0%) than those unvaccinated with prior infection (65.0%).

Conclusion: These results demonstrated that single infection does not confer effective protection against SARS-CoV-2.

Keywords: COVID-19; antibodies; long-lasting immunity; seroconversion; vaccination.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antibodies, Viral
  • COVID-19* / epidemiology
  • Follow-Up Studies
  • Humans
  • SARS-CoV-2
  • Spike Glycoprotein, Coronavirus*

Substances

  • Spike Glycoprotein, Coronavirus
  • Antibodies, Viral
  • spike protein, SARS-CoV-2

Grants and funding

This work was supported by the European Commission (European Virus Archive Global project (EVA GLOBAL, grant agreement No. 871029) of the Horizon 2020 research and innovation program). The material was provided by the European virus archive-Marseille (EVAM) under the label technological platforms of Aix-Marseille University. This research has been partially funded by EpiCoV and SAPRIS-SERO projects Institut national de la santé et de la recherche médicale (Inserm) and Direction de la recherche, des études, de l’évaluation, et des statistiques (Drees) (NCT04392388), and by the University of Corsica, France.